Humanscape Aims to Improve Drug Accessibility with Data from Myasthenia Gravis Patients

HumanScape, which operates the rare and intractable disease platform ‘RareNote’, announced on the 7th that it will expand treatment opportunities by substantiating the unmet medical needs of patients with myasthenia gravis through data. An analysis of ‘Patient-Generated Health Data (PGHD)’ collected from in-depth surveys targeting patients with myasthenia gravis revealed that 69% of moderate to severe patients (MGFA Class III·IV) have experienced treatment failure with steroids. This figure is about seven times that of the mild patient group. In the case of non-steroidal immunosuppressants, the failure rate in moderate to severe patient groups was 71%, showing a significant difference compared to 12% for mild patients. Myasthenia gravis is an autoimmune disease characterized by disturbed signaling between nerves and muscles, resulting in various symptoms such as drooping eyelids, double vision, and breathing difficulties. Currently, there is no cure, and treatment focuses on symptom management using steroids and immunosuppressants. HumanScape plans to utilize the patient data obtained this time as a key asset for new drug development and policy improvement. Along with the high rate of treatment failure, it has been confirmed that 44% of severe patients have experienced unemployment, indicating an economic impact. The quantifiable data will be submitted as evidence for the listing of new medications under health insurance coverage. Baek Ha-won, head of the RareNote project at HumanScape, said, “This survey is significant as it has documented the voices of patients suffering due to the limitations of existing treatment methods in data form, and based on RareNote’s data analysis capabilities, we will act as a bridge to improve access to new medications and expand health insurance coverage.”